Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity.

PubWeight™: 1.34‹?› | Rank: Top 10%

🔗 View Article (PMID 9368726)

Published in Clin Oncol (R Coll Radiol) on January 01, 1997

Authors

J M Henk1

Author Affiliations

1: Royal Marsden NHS Trust, London, UK.

Articles citing this

Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol (2008) 4.39

The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer. Support Care Cancer (2007) 1.18

Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event. BMC Med Res Methodol (2012) 1.01

Effective health care: management of head and neck cancers. Qual Saf Health Care (2005) 0.89

ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer (2013) 0.89

A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer. Radiat Oncol (2010) 0.83

The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review. Dysphagia (2015) 0.82

Increased likelihood of long-term gastrostomy tube dependence in head and neck cancer survivors without partners. Head Neck (2012) 0.81

Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma. Am J Clin Oncol (2015) 0.81

Factors associated with gastrostomy tube dependence after concurrent chemoradiotherapy for hypopharyngeal cancer. Support Care Cancer (2014) 0.79

Fractionation or chemoradiation for head and neck cancer? Clin Oncol (R Coll Radiol) (1998) 0.75

Adjuvant Radiation Therapy Alone for HPV Related Oropharyngeal Cancers with High Risk Features. PLoS One (2016) 0.75

Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. Br J Cancer (2004) 0.75